|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | AZD2811, INH-34, Barasertib-HQPA , Defosbarasertib | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
| 化学式 | C26H30FN7O3 |
|||
| 分子量 | 507.56 | CAS No. | 722544-51-6 | |
| Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (197.02 mM) | |
| Water | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
||||
| 製品説明 | Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) は、高選択的なAurora B阻害剤で、in vitroアッセイにおけるIC50値は0.37 nMです。Aurora AよりもAurora Bに対して約3700倍高い選択性を示します。第1相。 |
|---|---|
| in vitro | Barasertib (AZD1152-HQPA), a highly selective Aurora B inhibitor, causes polyploidy and apoptosis in many cancer cell lines. |
| in vivo | Barasertib (AZD1152-HQPA) is an aurora B kinase inhibitor, and has efficacy against RB1 / SCLC cell line xenografts, RB1 / SCLC PDXs, and autochthonous Rb1 / neuroendocrine tumors. |
| 細胞アッセイ | 細胞株 | NCI-H82 cells, SCLC and NSCLC cell lines |
|---|---|---|
| 濃度 | -- | |
| 反応時間 | -- | |
| 実験の流れ | -- |
|
| 動物実験 | 動物モデル | mouse models of RB1−/− neuroendocrine cancers |
| 投薬量 | i.v. | |
| 投与方法 |
|

Data from [Data independently produced by Nature, 2014, 508(7494), 118-22]

Data from [Data independently produced by J Exp Med, 2014, 10.1084/jem.20141123]

Data from [Oncogene, 2014, 33, 3550-60]
| High-throughput screening identifies Aurora kinase B as a critical therapeutic target for Merkel cell carcinoma [ Nat Commun, 2025, 16(1):1583] | PubMed: 39939315 |
| Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies [ Cell Rep Med, 2025, 6(2):101964] | PubMed: 39933527 |
| Aurora B controls microtubule stability to regulate abscission dynamics in stem cells [ Cell Rep, 2025, 44(2):115238] | PubMed: 39854207 |
| Identification of chemical inhibitors targeting long noncoding RNA through gene signature-based high throughput screening [ Int J Biol Macromol, 2025, 292:139119] | PubMed: 39722392 |
| Oversized cells activate global proteasome-mediated protein degradation to maintain cell size homeostasis [ Elife, 2025, 14e75393] | PubMed: 39791360 |
| The mechanoresponsive chromosomal passenger complex sustains furrow ingression under confinement [ J Mol Cell Biol, 2025, mjaf019] | PubMed: 40693957 |
| Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition [ Biochim Biophys Acta Mol Cell Res, 2025, 1872(7):120001] | PubMed: 40499687 |
| Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer [ Sci Rep, 2025, 15(1):3211] | PubMed: 39863788 |
| Nucleosome stability safeguards cell identity, stress resilience and healthy aging [ bioRxiv, 2025, 2025.09.17.676776] | PubMed: 41000743 |
| Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies [ Cell, 2024, 187(1):184-203.e28] | PubMed: 38181741 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。